Everything below concerns hexenoyl cap. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-15. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
The iodine pit, also called the iodine hole or xenon pit, is a temporary disabling of a nuclear reactor due to the buildup of short-lived neutron poisons in the reactor core. The main isotope responsible is 135Xe, mainly produced by beta decay of 135I. 135I is a weak neutron absorber, while 135Xe is the strongest known neutron absorber. When 135Xe builds up in the fuel rods of a reactor, it significantly lowers their reactivity, by absorbing a significant amount of the neutrons that provide the nuclear reaction. The presence of 135I and 135Xe in the reactor is one of the main reasons for its power fluctuations in reaction to change of control rod positions. The buildup of short-lived fission products acting as nuclear poisons is called reactor poisoning, or xenon poisoning. The buildup of stable or long-lived neutron poisons is called reactor slagging.
Gueriguian, cited Rezulin's potential to harm the liver and the heart, and he questioned its viability in lowering blood sugar for patients with adult-onset diabetes, recommending against the drug's approval. After complaints from the drugmaker, Gueriguian was removed on November 4, 1996, and his review was purged by the FDA. Gueriguian and the company had a single meeting at which Gueriguian used "intemperate" language; the company said its objections were based on inappropriate remarks made by Gueriguian. Parke-Davis said at the advisory committee that the risk of liver toxicity was comparable to placebo and that additional data of other studies confirmed this. According to Peter Gøtzsche, when the company provided these additional data one week after approval, they showed a substantially greater risk for liver toxicity. The FDA approved the drug on January 29, 1997, and it appeared in pharmacies in late March. At the time, Dr. Solomon Sobel, a director at the FDA overseeing diabetes drugs, said in a New York Times interview that adverse effects of troglitazone appeared to be rare and relatively mild. Glaxo Wellcome received approval from the British Medicines Control Agency (MCA) to market troglitazone, as Romozin, in July 1997. After reports of sudden liver failure in patients receiving the drug, Parke-Davis and the FDA added warnings to the drug label requiring monthly monitoring of liver enzyme levels. Glaxo Wellcome removed troglitazone from the market in Britain on December 1, 1997.
On 10 September 2008, Matthew Bryza said before the Commission on Security and Cooperation in Europe, "But there's much more to the story than that. The conflict certainly did not begin on August 7th. [...] Already we saw that the Russian peacekeepers were playing a role in providing a shield, we believe, to the South Ossetians who were shooting at the Georgian positions." After the war, Irakli Okruashvili, who served as Minister of Defence of Georgia, claimed that he and President Saakashvili had prepared plans to retake South Ossetia and Abkhazia in 2005. The alleged original plans intended a two-pronged offensive into South Ossetia. Saakashvili believed that a Russian response would be checked by the United States through diplomacy, so he did not order the taking of the Roki Tunnel. Georgian forces raced to contain the Russian forces, but were "outmaneuvered by the Russians." Okruashvili said that Russian response would be "inevitable" as after 2006, Russians "repositioned and improved their military infrastructure in the North Caucasus, Abkhazia, and South Ossetia." The Georgian Army could have defended a few major towns from the Russians, but President Saakashvili "let the Russians in to avoid criticism and appear more of a victim". In September 2008, Matthew Bryza said there was no disagreement between the intercepted phone conversations (which were presented as evidence of Russian invasion on 7 August) and August 7 statements of Georgian officials made during the phone calls between Bryza and Georgians.
Sources: en.wikipedia.org
The story and cast performances were positively received; Time Out magazine called it "flawed but impressive". Afterward, he starred in Rob Reiner's 2007 comedy The Bucket List opposite Jack Nicholson. The plot follows two terminally ill men on a road trip with a list of things to do before they die. The film grossed $175 million worldwide.
=== Autoimmune causes of acquired coagulation disorders === There are autoimmune causes of coagulation disorders. They include acquired antibodies to coagulation factors, termed inhibitors of coagulation. The main inhibitor is directed against clotting factor VIII. Another example is antiphospholipid syndrome, an autoimmune, hypercoagulable state.
== Medical use == Thermal pharmaceutical bags are designed to transport temperature-sensitive medications, protecting them from damaging temperatures, shocks, and light. Many vaccines are delicate biological substances that can lose part or all of their effectiveness if they are frozen, allowed to get too hot, or exposed to bright light. Such vaccines must be kept within a specified temperature range, typically 2 to 8 °C (36 to 46 °F), from manufacture to use. According to the World Health Organization, at least 7% of temperature-sensitive medical products suffer significant degradation in potency in transit.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.